Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02150213 · ClinicalTrials.gov registry record · Phase 2
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT02150213 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 59 participants.
The verdict
NCT02150213, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
Interventions
- PROCEDURE Biopsy
- DRUG BGG492
- PROCEDURE MRI, CT or ultrasound was permitted if MRI was contraindicated
- PROCEDURE Dexamethasone Supression Test
- PROCEDURE Sonogram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02150213
The ClinicalTrials.gov registry entry for NCT02150213 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT02150213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02150213 about?
NCT02150213 is a clinical study titled "Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492". To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
What is the current status of trial NCT02150213?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2014-08. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02150213?
The interventions under investigation include: Biopsy (PROCEDURE), BGG492 (DRUG), MRI, CT or ultrasound was permitted if MRI was contraindicated (PROCEDURE), Dexamethasone Supression Test (PROCEDURE), Sonogram (PROCEDURE).
Who is sponsoring clinical trial NCT02150213?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.